Live replicating and non-replicating vaccines
This page catalogs 4 smallpox and mpox vaccine products spanning the current FDA-licensed options and historical formulations. Smallpox vaccines represent the oldest vaccine lineage in history, with vaccinia-based inoculation dating to Edward Jenner's 1796 work. The modern portfolio includes both replicating (ACAM2000) and non-replicating (JYNNEOS) platforms, with JYNNEOS holding dual indication for both smallpox and mpox.
Last updated: April 2026.
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| JYNNEOS / Imvamune | Smallpox and monkeypox vaccine, live non-replicating | Bavarian Nordic | Live MVA (non-replicating) | FDA Licensed, 2019 | Dual indication smallpox/mpox |
| ACAM2000 | Smallpox and mpox (vaccinia) vaccine, live | Emergent BioSolutions | Live vaccinia (replicating) | FDA Licensed, 2007 | Replicating vaccinia; significant adverse event profile |
| Dryvax | Smallpox vaccine (dried calf lymph) | Wyeth | Live vaccinia | FDA Licensed; Discontinued | Historical standard; replaced by ACAM2000 |
| Lancy-Vaxina | Calf lymph smallpox vaccine | Swiss Serum Institute | Live viral (calf lymph) | Historical; Discontinued | Swiss smallpox vaccine; approximately 100-year production run |
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Historical context informed by Khan, Shaz, The Ultimate Vaccine Timeline.